Philip B. Adamson net worth and biography

Philip Adamson Biography and Net Worth

Chief Medical Officer of CVRx

Philip B. Adamson has served as the Company’s Chief Medical Officer since May 2024. Dr. Adamson previously served as Divisional Vice President and Chief Medical Officer of the Heart Failure division at Abbott Laboratories from February 2015 to May 2024. Prior to this, he served as Vice President and Medical Director at St. Jude Medical from February 2015 to January 2017. Dr. Adamson also previously served as Director of the Heart Failure Treatment Program at Oklahoma Heart Hospital from July 2005 to February 2015. Before beginning his traditional clinical practice, Dr. Adamson served as an Associate Professor at the University of Oklahoma Health Sciences Center from July 1995 to June 2005. Dr. Adamson received his M.D. and M.S. from the University of Oklahoma College of Medicine.

What is Philip B. Adamson's net worth?: The estimated net worth of Philip B. Adamson is at least $180.42 thousand as of March 2nd, 2026. Dr. Adamson owns 61,578 shares of CVRx stock worth more than $180,424 as of September 18th. This net worth evaluation does not reflect any other investments that Dr. Adamson may own. Learn More about Philip B. Adamson's net worth.
How do I contact Philip B. Adamson?: The corporate mailing address for Dr. Adamson and other CVRx executives is 9201 West Broadway Avenue, Suite 650, Minneapolis, MN, 55445. CVRx can also be reached via phone at (763) 416-2850 and via email at [email protected]. Learn More on Philip B. Adamson's contact information.
Has Philip B. Adamson been buying or selling shares of CVRx?: Philip B. Adamson has not been actively trading shares of CVRx during the past quarter. Most recently, Philip B. Adamson sold 1,262 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $7.90, for a transaction totalling $9,969.80. Following the completion of the sale, the insider now directly owns 61,578 shares of the company's stock, valued at $486,466.20. Learn More on Philip B. Adamson's trading history.
Who are CVRx's active insiders?: CVRx's insider roster includes Philip Adamson (Chief Medical Officer), Brent Binkowski (COO), Kevin Hykes ( President and CEO), Mudit Jain (Director), Kirk Nielsen (Director), and Paul Verrastro (Senior Advisor). Learn More on CVRx's active insiders.
Are insiders buying or selling shares of CVRx?: During the last twelve months, CVRx insiders bought shares 3 times. They purchased a total of 73,623 shares worth more than $376,740.93. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 58,803 shares worth more than $586,749.47. The most recent insider tranaction occured on August, 13th when COO Brent Binkowski bought 26,223 shares worth more than $76,308.93. Insiders at CVRx own 16.6% of the company. Learn More about insider trades at CVRx.
Information on this page was last updated on 8/13/2026.

Philip B. Adamson Insider Trading History at CVRx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/2/2026	Sell	1,262	$7.90	$9,969.80	61,578

Philip B. Adamson Buying and Selling Activity at CVRx

CVRx Company Overview

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Today's Range

Now: $2.99

$2.92

$3.03

50 Day Range

MA: $3.83

$2.37

$5.94

2 Week Range

Now: $2.99

$2.20

$11.30

Volume

204,864 shs

Average Volume

497,715 shs

Market Capitalization

$79.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76